Nuvation Bio received FDA approval for Ibtrozi (taletrectinib), targeting advanced ROS1-positive non-small cell lung cancer. Approval was based on robust response rates reported in multiple trials, including durable central nervous system disease control. Despite initial stock price decline post-announcement, the drug offers a new therapeutic option for patients with this rare genetic subtype, competing with established ROS1 inhibitors from major pharma companies.